Trilitas Gel
NDC Package 87143-200-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Trilitas (tazarotene) gel is tazarotene is used to treat psoriasis or acne. This formulation utilizes a gel delivery system. Marketed by Perfero Pharma, Inc., this product is identified by NDC 87143-200 and is authorized under FDA application ANDA214136.

Identification & Billing

NDC Package Code
87143-200-30
Package Description
1 TUBE in 1 CARTON / 30 g in 1 TUBE
Product Code
87143-200
11-Digit Billing Format
87143020030

Clinical Specifications

Proprietary Name
Trilitas
Non-Proprietary Name
Tazarotene
Substance Name
Tazarotene
Dosage Form
Gel - A semisolid3 dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion.4 A gel may contain suspended particles.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
TAZAROTENE 1 mg/g
Pharmacologic Class
Usage Information
Tazarotene is used to treat psoriasis or acne. It is a retinoid product related to Vitamin A. It works by affecting the growth of skin cells. The foam and lotion forms of this medication are only approved for use on acne.

Regulatory & Marketing

Labeler Name
Perfero Pharma, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA214136
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-15-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 87143-200-30 identifies a specific commercial package of 1 tube in 1 carton / 30 g in 1 tube of Trilitas, a human prescription drug labeled by Perfero Pharma, Inc.. This gel is formulated for topical use and contains tazarotene as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Perfero Pharma, Inc. on June 15, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Tazarotene is used to treat psoriasis or acne. It is a retinoid product related to Vitamin A. It works by affecting the growth of skin cells. The foam and lotion forms of this medication are only approved for use on acne.

How is this Perfero Pharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 87143020030. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
87143-200-30
11-Digit CMS (5-4-2)
87143-0200-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.